Proteomic analysis of multiple myeloma: Current status and future perspectives

Proteomics - Clinical Applications

Volumn 5, Issue 1-2, 2011, Pages 30-37

  Ge, Feng ^a   Bi, Li Jun ^b   Tao, Sheng Ce ^c   Xu, Xu dong ^a   Zhang, Zhi Ping ^d   Kitazato, Kaio ^e   Zhang, Xian En ^d  

^a INSTITUTE OF HYDROBIOLOGY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c Chinese National Human Genome Center at Shanghai   (China)

^d WUHAN INSTITUTE OF VIROLOGY   (China)

^e NAGASAKI UNIVERSITY   (Japan)

Author keywords

Biomarkers; MS; Multiple myeloma; Proteomics; PTM

Indexed keywords

ALBUMIN; ARSENIC TRIOXIDE; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BORTEZOMIB; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; OXYGEN 18; PROTEIN KINASE B; PROTEIN KINASE LYN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER RESISTANCE; CANCER STAGING; DISEASE MARKER; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN DEPHOSPHORYLATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; REPRODUCIBILITY; REVIEW; SIGNAL TRANSDUCTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79251552816     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000044     Document Type: Review

References (88)

1. Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., Anderson, K. C., Multiple myeloma. Lancet 2009, 374, 324-339.
2. Caers, J., Vande broek, I., De Raeve, H., Michaux, L. et al., Multiple myeloma - an update on diagnosis and treatment. Eur. J. Haematol. 2008, 81, 329-343.
3. Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R. et al., A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 2002, 346, 564-569.
4. Anderson, K. C., Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol. 2007, 35, 155-162.
5. Teoh, G., Anderson, K. C., Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am. 1997, 11, 27-42.
6. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K. et al., Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99, 1745-1757.
7. Rees-Unwin, K. S., Morgan, G. J., Davies, F. E., Proteomics and the haematologist. Clin. Lab. Haematol. 2004, 26, 77-86.
8. Thadikkaran, L., Siegenthaler, M. A., Crettaz, D., Queloz, P. A. et al., Recent advances in blood-related proteomics. Proteomics 2005, 5, 3019-3034.
9. Tassone, P., Tagliaferri, P., Rossi, M., Gaspari, M. et al., Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur. J. Cancer 2006, 42, 1530-1538.
10. Micallef, J., Dharsee, M., Chen, J., Ackloo, S. et al., Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. J. Hematol. Oncol. 2010, 3, 13.
11. Bommert, K., Bargou, R. C., Stuhmer, T., Signalling and survival pathways in multiple myeloma. Eur. J. Cancer 2006, 42, 1574-1580.
12. Chen, E. I., Yates, J. R., 3rd, Cancer proteomics by quantitative shotgun proteomics. Mol. Oncol. 2007, 1, 144-159.
13. Han, X., Aslanian, A., Yates, J. R., 3rd, Mass spectrometry for proteomics. Curr. Opin. Chem. Biol. 2008, 12, 483-490.
14. Alex, P., Gucek, M., Li, X., Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm. Bowel Dis. 2009, 15, 616-629.
15. Cravatt, B. F., Simon, G. M., Yates, J. R., 3rd, The biological impact of mass-spectrometry-based proteomics. Nature 2007, 450, 991-1000.
16. Yates, J. R., Ruse, C. I., Nakorchevsky, A., Proteomics by mass spectrometry: approaches, advances, and applications. Annu. Rev. Biomed. Eng. 2009, 11, 49-79.
17. Issaq, H., Veenstra, T., Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): advances and perspectives. Biotechniques 2008, 44, 697-698, 700.
18. Marko-Varga, G., Lindberg, H., Lofdahl, C. G., Jonsson, P. et al., Discovery of biomarker candidates within disease by protein profiling: principles and concepts. J. Proteome Res. 2005, 4, 1200-1212.
19. Unlu, M., Morgan, M. E., Minden, J. S., Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18, 2071-2077.
20. Lilley, K. S., Friedman, D. B., All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev. Proteomics 2004, 1, 401-409.
21. Friedman, D. B., Lilley, K. S., Optimizing the difference gel electrophoresis (DIGE) technology. Methods Mol. Biol. 2008, 428, 93-124.
22. Zieske, L. R., A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J. Exp. Bot. 2006, 57, 1501-1508.
23. Aggarwal, K., Choe, L. H., Lee, K. H., Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct. Genomic Proteomic 2006, 5, 112-120.
24. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
25. Elliott, M. H., Smith, D. S., Parker, C. E., Borchers, C., Current trends in quantitative proteomics. J. Mass Spectrom. 2009, 44, 1637-1660.
26. Mann, M., Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 2006, 7, 952-958.
27. Bachi, A., Bonaldi, T., Quantitative proteomics as a new piece of the systems biology puzzle. J. Proteomics 2008, 71, 357-367.
28. Duan, X., Kelsen, S. G., Clarkson, A. B. Jr., Ji, R., Merali, S., SILAC analysis of oxidative stress-mediated proteins in human pneumocytes: new role for treacle. Proteomics 2010, 10, 2165-2174.
29. Prokhorova, T. A., Rigbolt, K. T., Johansen, P. T., Henningsen, J. et al., Stable isotope labeling by amino acids in cell culture (SILAC) and quantitative comparison of the membrane proteomes of self-renewing and differentiating human embryonic stem cells. Mol. Cell. Proteomics 2009, 8, 959-970.
30. Zhang, L., Zhang, Z. P., Zhang, X. E., Lin, F. S., Ge, F., Quantitative proteomics analysis reveals BAG3 as a potential target to suppress severe acute respiratory syndrome coronavirus replication. J. Virol. 2010, 84, 6050-6059.
31. Yao, X., Freas, A., Ramirez, J., Demirev, P. A., Fenselau, C., Proteolytic 18O labeling for comparative proteomics: model studies with two serotypes of adenovirus. Anal. Chem. 2001, 73, 2836-2842.
32. Fenselau, C., Yao, X., Proteolytic labeling with 18O for comparative proteomics studies: preparation of 18O-labeled peptides and the 18O/16O peptide mixture. Methods Mol. Biol. 2007, 359, 135-142.
33. Mirgorodskaya, O. A., Kozmin, Y. P., Titov, M. I., Korner, R. et al., Quantitation of peptides and proteins by matrix-assisted laser desorption/ionization mass spectrometry using (18)O-labeled internal standards. Rapid Commun. Mass Spectrom. 2000, 14, 1226-1232.
34. Stewart, II., Thomson, T., Figeys, D., 18O labeling: a tool for proteomics. Rapid Commun. Mass Spectrom. 2001, 15, 2456-2465.
35. 18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol. Cell. Proteomics 2009, 8, 1453-1474.
36. Lee, H. J., Kang, M. J., Lee, E. Y., Cho, S. Y. et al., Application of a peptide-based PF2D platform for quantitative proteomics in disease biomarker discovery. Proteomics 2008, 8, 3371-3381.
37. 18O-labeling to identify biomarkers for cholangiocarcinoma. J. Proteome Res. 2008, 7, 4670-4677.
38. 18O stable isotope labeling for quantification of N-glycoproteome. J. Proteome Res. 2010, 9, 227-236.
39. Bonenfant, D., Schmelzle, T., Jacinto, E., Crespo, J. L. et al., Quantitation of changes in protein phosphorylation: a simple method based on stable isotope labeling and mass spectrometry. Proc. Natl. Acad. Sci. USA 2003, 100, 880-885.
40. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
41. Mallick, P., Schirle, M., Chen, S. S., Flory, M. R. et al., Computational prediction of proteotypic peptides for quantitative proteomics. Nat. Biotechnol. 2007, 25, 125-131.
42. Picotti, P., Bodenmiller, B., Mueller, L. N., Domon, B., Aebersold, R., Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009, 138, 795-806.
43. Jin, L. L., Tong, J., Prakash, A., Peterman, S. M. et al., Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry. J. Proteome Res. 2010, 9, 2752-2761.
44. Anderson, N. L., Anderson, N. G., Pearson, T. W., Borchers, C. H. et al., A human proteome detection and quantitation project. Mol. Cell. Proteomics 2009, 8, 883-886.
45. Kiehntopf, M., Siegmund, R., Deufel, T., Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin. Chem. Lab. Med. 2007, 45, 1435-1449.
46. Issaq, H. J., Conrads, T. P., Prieto, D. A., Tirumalai, R., Veenstra, T. D., SELDI-TOF MS for diagnostic proteomics. Anal. Chem. 2003, 75, 148A-155A.
47. De Bock, M., de Seny, D., Meuwis, M. A., Chapelle, J. P. et al., Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J. Biomed. Biotechnol. 2010, 906082.
48. Maurya, P., Meleady, P., Dowling, P., Clynes, M., Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007, 27, 1247-1255.
49. Whelan, L. C., Power, K. A., McDowell, D. T., Kennedy, J., Gallagher, W. M., Applications of SELDI-MS technology in oncology. J. Cell. Mol. Med. 2008, 12, 1535-1547.
50. Clarke, C. H., Buckley, J. A., Fung, E. T., SELDI-TOF-MS proteomics of breast cancer. Clin. Chem. Lab. Med. 2005, 43, 1314-1320.
51. Skytt, A., Thysell, E., Stattin, P., Stenman, U. H. et al., SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int. J. Cancer 2007, 121, 615-620.
52. Hundt, S., Haug, U., Brenner, H., Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1935-1953.
53. Stoica, G. E., Kuo, A., Aigner, A., Sunitha, I. et al., Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 2001, 276, 16772-16779.
54. Chernyak, A., Karavanov, A., Ogawa, Y., Kovac, P., Conjugating oligosaccharides to proteins by squaric acid diester chemistry: rapid monitoring of the progress of conjugation, and recovery of the unused ligand. Carbohydr. Res. 2001, 330, 479-486.
55. Chen, C. S., Zhu, H., Protein microarrays. Biotechniques 2006, 40, 423, 425, 427 passim.
56. Zhu, H., Bilgin, M., Bangham, R., Hall, D. et al., Global analysis of protein activities using proteome chips. Science 2001, 293, 2101-2105.
57. Reinders, J., Sickmann, A., Modificomics: posttranslational modifications beyond protein phosphorylation and glycosylation. Biomol. Eng. 2007, 24, 169-177.
58. Zhao, Y., Jensen, O. N., Modification-specific proteomics: strategies for characterization of post-translational modifications using enrichment techniques. Proteomics 2009, 9, 4632-4641.
59. Stone, K. L., Crawford, M., McMurray, W., Williams, N., Williams, K. R., Identification of proteins based on MS/MS spectra and location of posttranslational modifications. Methods Mol. Biol. 2007, 386, 57-77.
60. de Graauw, M., Hensbergen, P., van de Water, B., Phospho-proteomic analysis of cellular signaling. Electrophoresis 2006, 27, 2676-2686.
61. Schmelzle, K., White, F. M., Phosphoproteomic approaches to elucidate cellular signaling networks. Curr. Opin. Biotechnol. 2006, 17, 406-414.
62. Hoffert, J. D., Knepper, M. A., Taking aim at shotgun phosphoproteomics. Anal. Biochem. 2008, 375, 1-10.
63. Paradela, A., Albar, J. P., Advances in the analysis of protein phosphorylation. J. Proteome Res. 2008, 7, 1809-1818.
64. Johnson, S. A., Hunter, T., Phosphoproteomics finds its timing. Nat. Biotechnol. 2004, 22, 1093-1094.
65. Mazanek, M., Mituloviae, G., Herzog, F., Stingl, C. et al., Titanium dioxide as a chemo-affinity solid phase in offline phosphopeptide chromatography prior to HPLC-MS/MS analysis. Nat. Protoc. 2007, 2, 1059-1069.
66. Thingholm, T. E., Jensen, O. N., Larsen, M. R., Analytical strategies for phosphoproteomics. Proteomics 2009, 9, 1451-1468.
67. Kyono, Y., Sugiyama, N., Imami, K., Tomita, M., Ishihama, Y., Successive and selective release of phosphorylated peptides captured by hydroxy acid-modified metal oxide chromatography. J. Proteome Res. 2008, 7, 4585-4593.
68. Ogata, A., Chauhan, D., Teoh, G., Treon, S. P. et al., IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 1997, 159, 2212-2221.
69. Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M. et al., Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997, 89, 227-234.
70. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J. et al., Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10, 105-115.
71. Tu, Y., Gardner, A., Lichtenstein, A., The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000, 60, 6763-6770.
72. Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R. et al., Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 2006, 354, 1362-1369.
73. Durie, B. G., Salmon, S. E., A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36, 842-854.
74. Greipp, P. R., San Miguel, J., Durie, B. G., Crowley, J. J. et al., International staging system for multiple myeloma. J. Clin. Oncol. 2005, 23, 3412-3420.
75. Koomen, J. M., Haura, E. B., Bepler, G., Sutphen, R. et al., Proteomic contributions to personalized cancer care. Mol. Cell. Proteomics 2008, 7, 1780-1794.
76. Hong, H., Dragan, Y., Epstein, J., Teitel, C. et al., Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). Biomed. Chromatogr. Bioinformatics 2005, 6, S5.
77. Wang, Q. T., Li, Y. Z., Liang, Y. F., Hu, C. J. et al., Construction of a multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software. Anat. Rec. (Hoboken) 2009, 292, 604-610.
78. Xiao, C. L., Zhang, Z. P., Xiong, S., Lu, C. H. et al., Comparative proteomic analysis to discover potential therapeutic targets in human multiple myeloma. Proteomics Clin. Appl. 2009, 3, 1348-1360.
79. Rees-Unwin, K. S., Craven, R. A., Davenport, E., Hanrahan, S. et al., Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma. Br. J. Haematol. 2007, 139, 559-567.
80. Ge, F., Lu, X. P., Zeng, H. L., He, Q. Y. et al., Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J. Proteome Res. 2009, 8, 3006-3019.
81. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V. et al., The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101, 2377-2380.
82. Hsieh, F. Y., Tengstrand, E., Pekol, T. M., Guerciolini, R., Miwa, G., Elucidation of potential bortezomib response markers in mutliple myeloma patients. J. Pharm. Biomed. Anal. 2009, 49, 115-122.
83. St-Germain, J. R., Taylor, P., Tong, J., Jin, L. L. et al., Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc. Natl. Acad. Sci. USA 2009, 106, 20127-20132.
84. L'Hote, C. G., Knowles, M. A., Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp. Cell Res. 2005, 304, 417-431.
85. Pollett, J. B., Trudel, S., Stern, D., Li, Z. H., Stewart, A. K., Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 2002, 100, 3819-3821.
86. Xu, Y., Harder, K. W., Huntington, N. D., Hibbs, M. L., Tarlinton, D. M., Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005, 22, 9-18.
87. Stover, D. R., Furet, P., Lydon, N. B., Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J. Biol. Chem. 1996, 271, 12481-12487.
88. Ge, F., Xiao, C. L., Yin, X. F., Lu, C. H. et al., Phosphoproteomic analysis of primary human multiple myeloma cells. J. Proteomics 2010, 73, 1381-1390.